{"id":"117e589d427f","type":"article","url":"https://hartvaat.nl/2026/11/08/lp-a-variabiliteit-na-hartinfarct-ontslagmeting-als-eerste-stap-in-tweestapsstra/","title":"Lp(a)-variabiliteit na hartinfarct: ontslagmeting als eerste stap in tweestapsstrategie","title_en":"Variability of lipoprotein(a) levels in patients with acute myocardial infarction between admission, discharge, and follow-up.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"European journal of preventive cardiology","doi":"10.1093/eurjpc/zwag573","source_url":"https://doi.org/10.1093/eurjpc/zwag573","authors":["Tabassome Simon","Randa Khani Bittar","Alexandra Rousseau","Fabrice Prunier","Guillaume Cayla","Emile Ferrari","Thibault Lhermusier","Laurence Berard","Pascal Goube","Gilles Lemesle","Claire Bouleti","Yves Cottin","Helene Eltchaninoff","Dominique Bonnefont-Rousselot","Denis Angoulvant","Batric Popovic","François Schiele","Victor Aboyans","Etienne Puymirat","Gilles Barone-Rochette","Christophe Thuaire","Pierre Coste","Romain Gallet","Laurie Saulat-Dufour","Nicolas Danchin","Philippe Gabriel Steg","Franck Boccara"],"significance":5,"published":"2026-11-15","source_date":"2026-11-08","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"In a multicentre cohort of 1,561 patients following an acute myocardial infarction, researchers assessed the temporal variability of lipoprotein(a) [Lp(a)] levels from admission to 3–12 months follow-up. Although median Lp(a) remained stable, 31.5% of patients shifted categories over time. A discharge measurement ≤37 mg/dL reliably excluded follow-up levels >70 mg/dL with a misclassification rate of <1%, supporting a pragmatic two-step testing strategy to identify candidates for targeted Lp(a) therapies. External validation is needed before routine implementation, but the approach could streamline risk stratification and trial eligibility.","created":"2026-11-09T01:57:19Z","updated":"2026-11-09T01:57:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een cohort van 1561 patiënten na een acuut hartinfarct onderzochten onderzoekers de stabiliteit van lipoproteïne(a) [Lp(a)] tussen opname, ontslag en follow-up. Hoewel de mediane Lp(a)-waarde stabiel bleef, verschoven 31,5% van de patiënten van categorie. Een ontslagmeting ≤37 mg/dL sluit met een foutmarge van <1% uit dat de Lp(a)-waarde bij follow-up >70 mg/dL is, wat een pragmatische tweestapsstrategie suggereert om alleen patiënten met hogere waarden te hermeten. Dit kan de selectie voor nieuwe Lp(a)-therapieën efficiënter maken, mits extern gevalideerd.","abstract_original":"AIMS: Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease. Using Lp(a) concentrations measured during stable follow-up as the reference, we aimed to assess the temporal variability of Lp(a) after acute myocardial infarction (AMI) and to explore a pragmatic strategy for Lp(a) measurement. METHODS AND RESULTS: The FRENCHIE-Lp(a) cohort enrolled consecutive adults hospitalized for AMI in 21 centres. Lp(a) mass concentration, measured at admission, hospital discharge, and 3-12 months follow-up, was analysed both as a continuous and predefined categorical variable (≤20, >20-≤50, >50-≤70, >70 mg/dL). Assuming follow-up Lp(a) as the reference, we aimed to identify the threshold values that would allow us to accurately identify patients with Lp(a) > 70mg/dL, the threshold mostly used for patient selection in phase III trials of targeted Lp(a) therapies. A cumulative threshold analysis was performed to identify the Lp(a) value below which the misclassification rate (i.e. % of patients with follow-up Lp(a) > 70 mg/dL) remained <1%. Among 1561 patients (aged 61 ± 12 years; 21.3% women), median Lp(a) was 13 mg/dL at admission and remained stable over time (median difference overtime = 0 mg/dL). However, only 68.5% of patients remained in the same Lp(a) category overtime. In patients with discharge-Lp(a) ≤37 mg/dL (72.5% of the population), only 0.97% had Lp(a) >70 mg/dL at follow-up compared to 39.9% of those with discharge-Lp(a) >37 mg/dL. CONCLUSION: Although the median Lp(a) level remained stable between admission and follow-up, one-third of AMI patients shifted within Lp(a) categories over time. Pending external validation, an exploratory two-step strategy based on Lp(a) measurement at discharge, followed by repeat testing in patients with Lp(a) >37 mg/dL, showed a misclassification rate below 1% for identifying patients potentially needing intervention. REGISTRATION: Clinical trial Number: NCT04050956."}